Literature DB >> 1655663

Sero-epidemiological investigations on human herpesvirus 6 (HHV-6) infections using a newly developed early antigen assay.

S Iyengar1, P H Levine, D Ablashi, J Neequaye, G R Pearson.   

Abstract

Monoclonal antibodies (MAbs) were developed against immunodominant HHV-6 (GS isolate) late and early proteins. The major late protein was identified as a probable glycoprotein with a molecular weight of approximately 110 kDa (gp 110). Immunoblotting of the early antigen yielded proteins of 41 and 38 kDa (p41/38). The MAb to the early protein reacted with cells infected with 14 different HHV-6 isolates. In contrast, the MAb against the late protein reacted with only 10 of these isolates, indicating that there was strain variation in this glycoprotein. The percentage of antibody-positive sera reactive with gp110 in the ELISA ranged from 56% to 96% among the different serum donor categories. In contrast, only 10-30% of the sera were positive for antibodies to p41/38 with the exception of sera from patients with African Burkitt's lymphoma (ABL) and Hodgkin's disease (HD). These antibody patterns denote the presence of active HHV-6 replication in patients with ABL and HD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655663     DOI: 10.1002/ijc.2910490413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Recognition of a novel stage of betaherpesvirus latency in human herpesvirus 6.

Authors:  Kazuhiro Kondo; Junji Sashihara; Kazuya Shimada; Masaya Takemoto; Kiyoko Amo; Hiromi Miyagawa; Koichi Yamanishi
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  Transcriptional patterns of the pCD41 (U27) locus of human herpesvirus 6.

Authors:  Y Zhou; B Chandran; C Wood
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Definition of a divergent epitope that allows differential detection of early protein p41 from human herpesvirus 6 variants A and B.

Authors:  Y Xu; A Linde; H Dahl; G Winberg
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

5.  A novel cis element essential for stimulated transcription of the p41 promoter of human herpesvirus 6.

Authors:  J R Thompson; A D Agulnick; R P Ricciardi
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus.

Authors:  Z N Berneman; D V Ablashi; G Li; M Eger-Fletcher; M S Reitz; C L Hung; I Brus; A L Komaroff; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 7.  Classification of HHV-6A and HHV-6B as distinct viruses.

Authors:  Dharam Ablashi; Henri Agut; Roberto Alvarez-Lafuente; Duncan A Clark; Stephen Dewhurst; Dario DiLuca; Louis Flamand; Niza Frenkel; Robert Gallo; Ursula A Gompels; Per Höllsberg; Steven Jacobson; Mario Luppi; Paolo Lusso; Mauro Malnati; Peter Medveczky; Yasuko Mori; Philip E Pellett; Joshua C Pritchett; Koichi Yamanishi; Tetsushi Yoshikawa
Journal:  Arch Virol       Date:  2013-11-06       Impact factor: 2.574

8.  Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomavirus gene expression.

Authors:  M Chen; N Popescu; C Woodworth; Z Berneman; M Corbellino; P Lusso; D V Ablashi; J A DiPaolo
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

9.  DR7 encoded by human herpesvirus 6 promotes glioma development and progression.

Authors:  Bin Gu; Meng Li; Yan Zhang; Lingyun Li; Kun Yao; Shizhi Wang
Journal:  Cancer Manag Res       Date:  2019-03-12       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.